This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Lorlatinib - Indications, Dosage, Side Effects and Precautions — Description, Dosage, Side Effects | PillsCard
OTC
Lorlatinib - Indications, Dosage, Side Effects and Precautions
25 mg/1, Tablet, film coated
INN: LORLATINIB
Available in:
🇬🇧🇵🇹
Form
TABLET, FILM COATED
Dosage
25 mg/1
Route
ORAL
Storage
—
About This Product
Manufacturer
Pfizer Laboratories Div Pfizer Inc
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
ATC Code
L01ED05
Source
OPENFDA_NDC
Lorlatinib is indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) which has been already treated by
• For metastatic disease, crizotinib and at least one other ALK inhibitor; or
• For metastatic disease,alectinibas the first ALK inhibitor therapy; or
• For metastatic disease, ceritinib as the first ALK inhibitor therapy.
⚠️ Warnings
•Lorlatinib when given with a strong CYP3A inducer can increase the risk of serious hepatotoxicity. Discontinue strong CYP3A inducers before giving lorlatinib.
• Withhold and resume Lorlatininb at same or reduced dose or permanently discontinue Lorlatinib based on severity of CNS symptoms like seizures, hallucinations and changes in cognitive function, mood (including suicidal ideation), speech, mental status, and sleep.
• In case of hyperlipidemia, initiate or increase the dose of lipid-lowering agents. In case of atrioventricular block, withhold and resume Lorlatinib at same or reduced dose based on severity.
• In patients with suspected Interstitial Lung Disease/Pneumonitis, immediately stop Lorlatinib.
• Lorlatinib can cause fetal harm, hence females and males of reproductive age should use an effective non-hormonal method of contraception.
